Annual SGA
$29.38 M
+$8.26 M+39.09%
December 31, 2023
Summary
- As of February 7, 2025, INBX annual SGA is $29.38 million, with the most recent change of +$8.26 million (+39.09%) on December 31, 2023.
- During the last 3 years, INBX annual SGA has risen by +$22.55 million (+329.80%).
- INBX annual SGA is now at all-time high.
Performance
INBX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$7.90 M
-$85.46 M-91.53%
September 30, 2024
Summary
- As of February 7, 2025, INBX quarterly SGA is $7.90 million, with the most recent change of -$85.46 million (-91.53%) on September 30, 2024.
- Over the past year, INBX quarterly SGA has dropped by -$85.46 million (-91.53%).
- INBX quarterly SGA is now -91.53% below its all-time high of $93.37 million, reached on June 30, 2024.
Performance
INBX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.38 B
+$461.86 M+25.09%
September 30, 2024
Summary
- As of February 7, 2025, INBX TTM SGA is -$1.38 billion, with the most recent change of +$461.86 million (+25.09%) on September 30, 2024.
- Over the past year, INBX TTM SGA has dropped by -$1.49 billion (-1323.08%).
- INBX TTM SGA is now -6253.55% below its all-time high of -$21.70 million.
Performance
INBX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
INBX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.1% | -91.5% | -1323.1% |
| 3 y3 years | +329.8% | +48.2% | -6541.4% |
| 5 y5 years | +531.3% | +48.2% | -6541.4% |
INBX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +137.8% | -91.5% | +192.8% | -76.1% | +39.9% |
| 5 y | 5-year | at high | +329.8% | -91.5% | +438.8% | -1014.3% | +39.9% |
| alltime | all time | at high | +1026.1% | -91.5% | +767.6% | -6253.6% | +39.9% |
Inhibrx Biosciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $7.90 M(-91.5%) | $112.75 M(+0.0%) |
| Jun 2024 | - | $93.37 M(+963.2%) | $112.74 M(+323.3%) |
| Mar 2024 | - | $8.78 M(+225.4%) | $26.63 M(+14.9%) |
| Dec 2023 | $29.38 M(+39.1%) | $2.70 M(-65.8%) | $23.18 M(-10.2%) |
| Sep 2023 | - | $7.89 M(+8.6%) | $25.81 M(+10.9%) |
| Jun 2023 | - | $7.26 M(+36.2%) | $23.27 M(+8.7%) |
| Mar 2023 | - | $5.33 M(+0.2%) | $21.41 M(+1.3%) |
| Dec 2022 | $21.12 M(+71.0%) | $5.32 M(-0.4%) | $21.12 M(+8.6%) |
| Sep 2022 | - | $5.35 M(-1.0%) | $19.45 M(+14.7%) |
| Jun 2022 | - | $5.40 M(+6.9%) | $16.95 M(+17.7%) |
| Mar 2022 | - | $5.05 M(+38.6%) | $14.40 M(+16.5%) |
| Dec 2021 | $12.36 M | $3.65 M(+28.0%) | $12.36 M(+13.1%) |
| Sep 2021 | - | $2.85 M(-0.2%) | $10.93 M(+12.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $2.85 M(-5.2%) | $9.70 M(+15.8%) |
| Mar 2021 | - | $3.01 M(+35.8%) | $8.38 M(+22.6%) |
| Dec 2020 | $6.84 M(-24.2%) | $2.21 M(+36.6%) | $6.84 M(-24.5%) |
| Sep 2020 | - | $1.62 M(+5.9%) | $9.05 M(+1.6%) |
| Jun 2020 | - | $1.53 M(+4.4%) | $8.91 M(-1.2%) |
| Mar 2020 | - | $1.47 M(-66.9%) | $9.02 M(0.0%) |
| Dec 2019 | $9.02 M(+93.8%) | $4.43 M(+199.4%) | $9.02 M(+96.7%) |
| Sep 2019 | - | $1.48 M(-9.5%) | $4.58 M(+47.7%) |
| Jun 2019 | - | $1.64 M(+11.5%) | $3.10 M(+26.3%) |
| Mar 2019 | - | $1.47 M(+48.3%) | $2.46 M(+29.3%) |
| Dec 2018 | $4.65 M(+78.4%) | - | - |
| Jun 2018 | - | $989.00 K(+8.6%) | $1.90 M(+108.6%) |
| Mar 2018 | - | $911.00 K | $911.00 K |
| Dec 2017 | $2.61 M | - | - |
FAQ
- What is Inhibrx Biosciences annual SGA?
- What is the all time high annual SGA for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual SGA year-on-year change?
- What is Inhibrx Biosciences quarterly SGA?
- What is the all time high quarterly SGA for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly SGA year-on-year change?
- What is Inhibrx Biosciences TTM SGA?
- What is the all time high TTM SGA for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM SGA year-on-year change?
What is Inhibrx Biosciences annual SGA?
The current annual SGA of INBX is $29.38 M
What is the all time high annual SGA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual SGA is $29.38 M
What is Inhibrx Biosciences annual SGA year-on-year change?
Over the past year, INBX annual SGA has changed by +$8.26 M (+39.09%)
What is Inhibrx Biosciences quarterly SGA?
The current quarterly SGA of INBX is $7.90 M
What is the all time high quarterly SGA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly SGA is $93.37 M
What is Inhibrx Biosciences quarterly SGA year-on-year change?
Over the past year, INBX quarterly SGA has changed by -$85.46 M (-91.53%)
What is Inhibrx Biosciences TTM SGA?
The current TTM SGA of INBX is -$1.38 B
What is the all time high TTM SGA for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM SGA is -$21.70 M
What is Inhibrx Biosciences TTM SGA year-on-year change?
Over the past year, INBX TTM SGA has changed by -$1.49 B (-1323.08%)